Accuray Announces 1-for-40 Reverse Stock Split

Accuray approved a 1-for-40 reverse stock split, effective November 9, 2026, intended to raise its per-share trading price and help regain compliance with Nasdaq’s minimum bid-price requirement. The split will reduce common shares outstanding from approximately 120.2 million to 3.0 million and authorized common shares from 400 million to 10 million; ownership percentages are otherwise unchanged, subject to fractional-share treatment.

Analysis

The split is a listing-compliance maneuver, not a change in enterprise value or operating capacity. The immediate setup is therefore mainly technical: a mechanically higher quoted price may improve Nasdaq compliance, but it does not establish that the price can be sustained. Around the Nov. 9 conversion, adjusted chart history, fractional-share cash-outs and broker processing may amplify noise in an already small-share-count stock; avoid reading the nominal price jump as a return signal.

The capital-structure detail is more consequential than the ratio itself. After the proportional reduction, authorized common shares still exceed issued shares by roughly 7 million, or more than twice the post-split issued count. That leaves meaningful common issuance capacity; the unchanged preferred authorization is a separate dilution overhang whose terms and potential conversion must be checked in filings. Thus, the split does not eliminate financing risk, and any future capital raise could be dilutive even with fewer shares outstanding.

Days: expect elevated volatility and possible liquidity/borrow distortions around the effective date. Over 1–3 months, the key catalyst is whether ARAY maintains the required bid price and whether filings show improvement in backlog conversion, margins, cash generation and debt-covenant headroom. Over 6–18 months, those fundamentals—not the split—determine whether listing risk and dilution pressure recede. The contrarian point: a reverse split is a negative signal about prior trading performance, but it is not itself proof of imminent distress or a short signal; the compliance cure may reduce delisting risk if sustained.

Key Decisions for Investors

• No standalone directional trade on the split. Treat Nov. 9 price action as mechanically adjusted and avoid interpreting the nominal price increase as value creation.
• Put ARAY on a post-split compliance watch: verify the actual split-adjusted opening and subsequent bid-price behavior, and reassess if the stock fails to sustain the Nasdaq threshold or the company reports a further compliance problem.
• Before taking a longer-term position, review the latest 10-K/10-Q and security terms for debt-covenant headroom, cash needs, authorized-share usage, equity awards, and the rights/conversion terms of preferred stock. These determine whether the remaining issuance capacity becomes a material dilution catalyst.
• Falsifiers for a bearish dilution/compliance view: sustained bid-price compliance accompanied by improving backlog-to-revenue conversion, gross-margin trend and cash/covenant disclosures. Deteriorating covenant headroom, weak conversion or renewed listing concerns would strengthen it.